hVIVO (LON:HVO) Stock Crosses Below Fifty Day Moving Average – What’s Next?

hVIVO plc (LON:HVO) passed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of GBX 6.36 and traded as low as GBX 5.72. hVIVO shares last traded at GBX 5.73, with a volume of 403,892 shares changing hands.

Analyst Ratings Changes

Separately, Peel Hunt restated a “buy” rating and set a GBX 14 price target on shares of hVIVO in a research note on Monday, October 12th. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of GBX 16.33.

hVIVO Stock Performance

The company has a debt-to-equity ratio of 43.38, a quick ratio of 1.16 and a current ratio of 1.21. The company has a market capitalization of £38.89 million, a price-to-earnings ratio of -3.17 and a beta of 1.69. The firm has a 50-day simple moving average of GBX 6.34 and a two-hundred day simple moving average of GBX 7.14.

hVIVO (LON:HVO) last issued its quarterly earnings results on Tuesday, September 15th. The company reported GBX (0.82) earnings per share (EPS) for the quarter. hVIVO had a negative return on equity of 35.13% and a negative net margin of 31.76%. On average, sell-side analysts anticipate that hVIVO plc will post 1.55 EPS for the current fiscal year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.